Updated: ESMO embargo break leads cancer conference to release data for Bristol Myers, J&J, Novartis, AstraZeneca

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Reynald Castañeda

Deputy Editor

A broken embargo on the highest-profile abstracts at this year’s European Society for Medical Oncology has forced the conference organizer to release data from the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: ESMO embargo break leads cancer conference to release data for Bristol Myers, J&J, Novartis, AstraZeneca

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

Up­dat­ed: ES­MO em­bar­go break leads can­cer con­fer­ence to re­lease da­ta for Bris­tol My­ers, J&J, No­var­tis, As­traZeneca

News Reporter

Senior Reporter

Deputy Editor

Sign up to read this article for free.

Updated: ESMO embargo break leads cancer conference to release data for Bristol Myers, J&J, Novartis, AstraZeneca